Concepts (271)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatectomy | 39 | 2022 | 64 | 10.780 |
Why?
|
| Liver Neoplasms | 31 | 2022 | 105 | 9.690 |
Why?
|
| Portal Vein | 30 | 2022 | 47 | 8.610 |
Why?
|
| Liver | 21 | 2022 | 160 | 6.740 |
Why?
|
| Liver Regeneration | 17 | 2022 | 25 | 4.980 |
Why?
|
| Colorectal Neoplasms | 13 | 2021 | 112 | 3.400 |
Why?
|
| Ligation | 22 | 2022 | 38 | 2.490 |
Why?
|
| Embolization, Therapeutic | 6 | 2021 | 60 | 2.260 |
Why?
|
| Laparoscopy | 6 | 2021 | 198 | 1.640 |
Why?
|
| Hepatic Stellate Cells | 2 | 2020 | 3 | 1.310 |
Why?
|
| Postoperative Complications | 13 | 2022 | 931 | 1.260 |
Why?
|
| Liver Diseases | 2 | 2018 | 35 | 1.120 |
Why?
|
| Cause of Death | 3 | 2017 | 64 | 1.060 |
Why?
|
| Registries | 9 | 2019 | 188 | 1.040 |
Why?
|
| Liver Failure | 4 | 2019 | 11 | 0.950 |
Why?
|
| Humans | 56 | 2024 | 28408 | 0.940 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2021 | 27 | 0.900 |
Why?
|
| Treatment Outcome | 20 | 2021 | 3615 | 0.840 |
Why?
|
| Hypoxia | 2 | 2020 | 36 | 0.810 |
Why?
|
| Hypertrophy | 5 | 2022 | 24 | 0.810 |
Why?
|
| Organ Size | 9 | 2019 | 100 | 0.760 |
Why?
|
| Sarcopenia | 1 | 2021 | 31 | 0.730 |
Why?
|
| Male | 36 | 2021 | 15273 | 0.710 |
Why?
|
| Retrospective Studies | 17 | 2022 | 3609 | 0.700 |
Why?
|
| Neovascularization, Pathologic | 1 | 2020 | 36 | 0.680 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2020 | 71 | 0.670 |
Why?
|
| Kidney Transplantation | 5 | 2021 | 133 | 0.650 |
Why?
|
| Organ Sparing Treatments | 1 | 2019 | 11 | 0.630 |
Why?
|
| Middle Aged | 26 | 2019 | 9254 | 0.620 |
Why?
|
| Hepatomegaly | 1 | 2018 | 7 | 0.620 |
Why?
|
| Reperfusion Injury | 1 | 2018 | 6 | 0.620 |
Why?
|
| Neuroendocrine Tumors | 5 | 2019 | 51 | 0.620 |
Why?
|
| Publication Bias | 1 | 2018 | 6 | 0.610 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 320 | 0.600 |
Why?
|
| Antioxidants | 1 | 2018 | 64 | 0.600 |
Why?
|
| Reactive Oxygen Species | 1 | 2018 | 119 | 0.590 |
Why?
|
| Oxidative Stress | 1 | 2018 | 107 | 0.590 |
Why?
|
| Bibliometrics | 1 | 2018 | 31 | 0.590 |
Why?
|
| Female | 31 | 2021 | 15708 | 0.590 |
Why?
|
| Neovascularization, Physiologic | 1 | 2017 | 24 | 0.570 |
Why?
|
| Length of Stay | 5 | 2021 | 328 | 0.530 |
Why?
|
| Pancreatic Neoplasms | 4 | 2024 | 97 | 0.520 |
Why?
|
| Therapies, Investigational | 1 | 2016 | 5 | 0.520 |
Why?
|
| Aged | 20 | 2019 | 9262 | 0.510 |
Why?
|
| Animals | 8 | 2021 | 3780 | 0.480 |
Why?
|
| Graft Rejection | 4 | 2008 | 71 | 0.450 |
Why?
|
| Catheter Ablation | 1 | 2015 | 72 | 0.440 |
Why?
|
| Liver Transplantation | 3 | 2015 | 96 | 0.430 |
Why?
|
| Hepatic Veins | 4 | 2022 | 10 | 0.420 |
Why?
|
| Blood Loss, Surgical | 3 | 2019 | 59 | 0.410 |
Why?
|
| Time Factors | 9 | 2019 | 1490 | 0.410 |
Why?
|
| Prognosis | 8 | 2020 | 825 | 0.410 |
Why?
|
| Risk Factors | 10 | 2019 | 2408 | 0.400 |
Why?
|
| Feasibility Studies | 4 | 2016 | 231 | 0.380 |
Why?
|
| Operative Time | 4 | 2019 | 93 | 0.350 |
Why?
|
| Survival Rate | 6 | 2018 | 356 | 0.350 |
Why?
|
| Follow-Up Studies | 7 | 2018 | 1858 | 0.340 |
Why?
|
| Adenocarcinoma | 2 | 2024 | 147 | 0.340 |
Why?
|
| Models, Animal | 3 | 2020 | 115 | 0.330 |
Why?
|
| Tissue Donors | 2 | 2021 | 84 | 0.330 |
Why?
|
| Neoplasm Staging | 5 | 2018 | 371 | 0.330 |
Why?
|
| Random Allocation | 3 | 2018 | 129 | 0.320 |
Why?
|
| Isoantibodies | 2 | 2006 | 8 | 0.320 |
Why?
|
| Intestinal Neoplasms | 2 | 2018 | 11 | 0.310 |
Why?
|
| Stomach Neoplasms | 2 | 2018 | 36 | 0.300 |
Why?
|
| Antibodies, Neoplasm | 1 | 2008 | 13 | 0.300 |
Why?
|
| Swine | 2 | 2018 | 81 | 0.290 |
Why?
|
| Pancreas Transplantation | 2 | 2021 | 17 | 0.290 |
Why?
|
| Death | 1 | 2008 | 47 | 0.290 |
Why?
|
| Vascular Surgical Procedures | 2 | 2019 | 26 | 0.290 |
Why?
|
| Adult | 15 | 2019 | 8097 | 0.280 |
Why?
|
| Patient Selection | 4 | 2018 | 206 | 0.280 |
Why?
|
| Rats, Wistar | 2 | 2017 | 52 | 0.280 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 199 | 0.270 |
Why?
|
| Immunosuppressive Agents | 1 | 2008 | 140 | 0.270 |
Why?
|
| Rats | 2 | 2020 | 678 | 0.270 |
Why?
|
| Switzerland | 3 | 2021 | 7 | 0.270 |
Why?
|
| Plasmapheresis | 1 | 2006 | 12 | 0.260 |
Why?
|
| Risk Assessment | 5 | 2019 | 676 | 0.260 |
Why?
|
| HLA Antigens | 1 | 2006 | 17 | 0.260 |
Why?
|
| Antibody Formation | 1 | 2006 | 18 | 0.260 |
Why?
|
| Philosophy, Medical | 1 | 2004 | 3 | 0.240 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2024 | 6 | 0.220 |
Why?
|
| Spirituality | 1 | 2004 | 80 | 0.220 |
Why?
|
| Tissue and Organ Procurement | 3 | 2012 | 35 | 0.200 |
Why?
|
| Ultrasonography | 3 | 2021 | 243 | 0.200 |
Why?
|
| Multivariate Analysis | 4 | 2019 | 331 | 0.200 |
Why?
|
| Cell Proliferation | 2 | 2020 | 178 | 0.190 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 986 | 0.190 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2021 | 13 | 0.190 |
Why?
|
| Databases, Factual | 3 | 2019 | 358 | 0.190 |
Why?
|
| Organ Transplantation | 1 | 2021 | 33 | 0.190 |
Why?
|
| Biomarkers | 3 | 2020 | 596 | 0.190 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 24 | 0.190 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 190 | 0.190 |
Why?
|
| Graft vs Host Disease | 1 | 2021 | 55 | 0.180 |
Why?
|
| Hospitals | 1 | 2021 | 156 | 0.180 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 112 | 0.180 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2020 | 3 | 0.170 |
Why?
|
| Adrenalectomy | 1 | 2019 | 4 | 0.170 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 75 | 0.170 |
Why?
|
| Brazil | 2 | 2016 | 41 | 0.170 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2019 | 13 | 0.170 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 81 | 0.170 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2019 | 14 | 0.170 |
Why?
|
| Parenchymal Tissue | 1 | 2019 | 2 | 0.160 |
Why?
|
| Conversion to Open Surgery | 1 | 2019 | 4 | 0.160 |
Why?
|
| Hospital Mortality | 3 | 2015 | 147 | 0.160 |
Why?
|
| Liver Function Tests | 4 | 2017 | 21 | 0.160 |
Why?
|
| Abdominal Neoplasms | 1 | 2019 | 15 | 0.160 |
Why?
|
| Preoperative Period | 1 | 2019 | 81 | 0.160 |
Why?
|
| Gallium Radioisotopes | 1 | 2018 | 3 | 0.160 |
Why?
|
| Paracrine Communication | 1 | 2018 | 4 | 0.160 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2018 | 13 | 0.160 |
Why?
|
| Culture Media, Conditioned | 1 | 2018 | 17 | 0.160 |
Why?
|
| Organometallic Compounds | 1 | 2018 | 19 | 0.160 |
Why?
|
| Cytoprotection | 1 | 2018 | 9 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2018 | 20 | 0.160 |
Why?
|
| Hepatocytes | 1 | 2018 | 11 | 0.150 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2018 | 24 | 0.150 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 34 | 0.150 |
Why?
|
| Anesthesia | 1 | 2018 | 31 | 0.150 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 44 | 0.150 |
Why?
|
| Venous Thromboembolism | 1 | 2019 | 36 | 0.150 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 46 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2017 | 730 | 0.150 |
Why?
|
| Pulmonary Embolism | 1 | 2019 | 64 | 0.150 |
Why?
|
| Models, Biological | 1 | 2020 | 326 | 0.150 |
Why?
|
| Logistic Models | 3 | 2016 | 395 | 0.150 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 249 | 0.150 |
Why?
|
| Survival Analysis | 2 | 2017 | 267 | 0.140 |
Why?
|
| Portal Pressure | 1 | 2017 | 5 | 0.140 |
Why?
|
| Liver Circulation | 1 | 2017 | 6 | 0.140 |
Why?
|
| Gastric Bypass | 1 | 2018 | 70 | 0.140 |
Why?
|
| Apoptosis | 1 | 2018 | 205 | 0.140 |
Why?
|
| Hyperplasia | 1 | 2017 | 20 | 0.140 |
Why?
|
| Fatty Liver | 1 | 2017 | 31 | 0.140 |
Why?
|
| Melanoma | 1 | 2017 | 60 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 330 | 0.140 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 735 | 0.130 |
Why?
|
| Cell Hypoxia | 1 | 2016 | 11 | 0.130 |
Why?
|
| Cholangiocarcinoma | 1 | 2016 | 3 | 0.130 |
Why?
|
| Bile Duct Neoplasms | 1 | 2016 | 5 | 0.130 |
Why?
|
| Signal Transduction | 1 | 2018 | 447 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 177 | 0.130 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 619 | 0.130 |
Why?
|
| Primary Graft Dysfunction | 1 | 2015 | 5 | 0.120 |
Why?
|
| Obesity | 1 | 2018 | 321 | 0.120 |
Why?
|
| Methyl Ethers | 1 | 2015 | 6 | 0.120 |
Why?
|
| Propofol | 1 | 2015 | 9 | 0.120 |
Why?
|
| Anesthetics, Intravenous | 1 | 2015 | 10 | 0.120 |
Why?
|
| Anesthetics, Inhalation | 1 | 2015 | 12 | 0.120 |
Why?
|
| Transplantation Conditioning | 1 | 2015 | 43 | 0.120 |
Why?
|
| Cohort Studies | 3 | 2017 | 1926 | 0.120 |
Why?
|
| Safety | 1 | 2014 | 45 | 0.120 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2016 | 122 | 0.120 |
Why?
|
| Surgeons | 1 | 2016 | 89 | 0.120 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 89 | 0.110 |
Why?
|
| Viscera | 1 | 2013 | 2 | 0.110 |
Why?
|
| Vascular Patency | 1 | 2013 | 18 | 0.110 |
Why?
|
| Renal Artery | 1 | 2013 | 8 | 0.110 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2013 | 12 | 0.110 |
Why?
|
| Aneurysm | 1 | 2013 | 10 | 0.110 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2013 | 21 | 0.110 |
Why?
|
| Endovascular Procedures | 1 | 2013 | 34 | 0.100 |
Why?
|
| Stents | 1 | 2013 | 86 | 0.100 |
Why?
|
| Blood Transfusion | 1 | 2012 | 67 | 0.100 |
Why?
|
| Linear Models | 1 | 2012 | 251 | 0.100 |
Why?
|
| Bilirubin | 2 | 2016 | 11 | 0.100 |
Why?
|
| Resource Allocation | 1 | 2011 | 4 | 0.100 |
Why?
|
| Health Care Rationing | 1 | 2011 | 6 | 0.100 |
Why?
|
| End Stage Liver Disease | 1 | 2011 | 13 | 0.100 |
Why?
|
| Liver Cirrhosis | 2 | 2012 | 45 | 0.090 |
Why?
|
| Histocompatibility Testing | 1 | 2009 | 2 | 0.090 |
Why?
|
| HLA-C Antigens | 1 | 2009 | 9 | 0.080 |
Why?
|
| Disease-Free Survival | 2 | 2019 | 177 | 0.080 |
Why?
|
| Antilymphocyte Serum | 1 | 2008 | 4 | 0.080 |
Why?
|
| Alemtuzumab | 1 | 2008 | 5 | 0.080 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2008 | 7 | 0.080 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2007 | 3 | 0.070 |
Why?
|
| Glomerular Filtration Rate | 1 | 2008 | 53 | 0.070 |
Why?
|
| Blood Vessels | 1 | 2007 | 14 | 0.070 |
Why?
|
| Immunocompromised Host | 1 | 2008 | 46 | 0.070 |
Why?
|
| Kidney Failure, Chronic | 1 | 2009 | 165 | 0.070 |
Why?
|
| Graft Survival | 1 | 2008 | 102 | 0.070 |
Why?
|
| Heart Transplantation | 1 | 2007 | 30 | 0.070 |
Why?
|
| Cytomegalovirus Infections | 1 | 2008 | 35 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2008 | 94 | 0.070 |
Why?
|
| Incidence | 2 | 2021 | 773 | 0.070 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2007 | 113 | 0.070 |
Why?
|
| Aged, 80 and over | 4 | 2017 | 4853 | 0.070 |
Why?
|
| HLA-DP Antigens | 1 | 2006 | 1 | 0.060 |
Why?
|
| Complement C4b | 1 | 2006 | 1 | 0.060 |
Why?
|
| Body Mass Index | 2 | 2018 | 465 | 0.060 |
Why?
|
| Peptide Fragments | 1 | 2006 | 77 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2021 | 1805 | 0.060 |
Why?
|
| Religion and Medicine | 1 | 2004 | 24 | 0.060 |
Why?
|
| Anesthesia, Intravenous | 1 | 2024 | 6 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2021 | 1143 | 0.060 |
Why?
|
| Anesthesia, General | 1 | 2024 | 28 | 0.060 |
Why?
|
| Hospitals, University | 2 | 2018 | 28 | 0.060 |
Why?
|
| Delphi Technique | 1 | 2022 | 28 | 0.050 |
Why?
|
| Consensus | 1 | 2022 | 98 | 0.050 |
Why?
|
| Naphthoquinones | 1 | 2021 | 5 | 0.050 |
Why?
|
| Mice | 2 | 2021 | 1461 | 0.050 |
Why?
|
| Benzofurans | 1 | 2021 | 7 | 0.050 |
Why?
|
| Aniline Compounds | 1 | 2021 | 36 | 0.050 |
Why?
|
| Transplant Recipients | 1 | 2021 | 22 | 0.050 |
Why?
|
| Sulfonamides | 1 | 2021 | 41 | 0.050 |
Why?
|
| Pancreas | 1 | 2021 | 33 | 0.050 |
Why?
|
| Contrast Media | 1 | 2021 | 75 | 0.050 |
Why?
|
| Cold Ischemia | 2 | 2011 | 3 | 0.050 |
Why?
|
| Mitotane | 1 | 2019 | 3 | 0.040 |
Why?
|
| Kidney | 1 | 2021 | 175 | 0.040 |
Why?
|
| Preoperative Care | 1 | 2020 | 125 | 0.040 |
Why?
|
| Argentina | 1 | 2019 | 1 | 0.040 |
Why?
|
| Blood Coagulation Disorders | 1 | 2019 | 16 | 0.040 |
Why?
|
| United States | 2 | 2018 | 2197 | 0.040 |
Why?
|
| Digestive System Neoplasms | 1 | 2018 | 5 | 0.040 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2018 | 16 | 0.040 |
Why?
|
| Serum Albumin | 1 | 2019 | 24 | 0.040 |
Why?
|
| Europe | 1 | 2019 | 66 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 307 | 0.040 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2018 | 8 | 0.040 |
Why?
|
| Thymus Neoplasms | 1 | 2018 | 11 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 102 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2019 | 90 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 241 | 0.040 |
Why?
|
| Radionuclide Imaging | 1 | 2017 | 43 | 0.040 |
Why?
|
| Salvage Therapy | 1 | 2017 | 35 | 0.040 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2017 | 25 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2019 | 331 | 0.030 |
Why?
|
| Edema | 1 | 2017 | 25 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 1216 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2017 | 163 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 2017 | 70 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2017 | 108 | 0.030 |
Why?
|
| Rabbits | 1 | 2017 | 185 | 0.030 |
Why?
|
| Italy | 1 | 2016 | 11 | 0.030 |
Why?
|
| Medical Audit | 1 | 2016 | 6 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 206 | 0.030 |
Why?
|
| Hospitals, High-Volume | 1 | 2016 | 8 | 0.030 |
Why?
|
| Age Factors | 1 | 2018 | 781 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 362 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2016 | 66 | 0.030 |
Why?
|
| Belgium | 1 | 2015 | 1 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2015 | 15 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 86 | 0.030 |
Why?
|
| Sarcoma | 1 | 2017 | 144 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 352 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2015 | 268 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 492 | 0.030 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2013 | 21 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 553 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 409 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2015 | 593 | 0.030 |
Why?
|
| Waiting Lists | 1 | 2011 | 17 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2012 | 75 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2011 | 68 | 0.020 |
Why?
|
| Immunization | 1 | 2009 | 17 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2009 | 14 | 0.020 |
Why?
|
| Algorithms | 1 | 2012 | 377 | 0.020 |
Why?
|
| Histocompatibility | 1 | 2007 | 3 | 0.020 |
Why?
|
| Receptors, CXCR3 | 1 | 2007 | 4 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2007 | 26 | 0.020 |
Why?
|
| Child | 1 | 2012 | 1421 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2007 | 281 | 0.020 |
Why?
|
| Wisconsin | 1 | 2006 | 4 | 0.020 |
Why?
|
| Kidney Tubules | 1 | 2006 | 8 | 0.020 |
Why?
|
| Atrophy | 1 | 2006 | 93 | 0.020 |
Why?
|
| Kidney Glomerulus | 1 | 2006 | 48 | 0.020 |
Why?
|